Benign Prostatic Hyperplasia (BPH)

2
Pipeline Programs
3
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Pierre Fabre
Pierre FabreFrance - Aignan
2 programs
2
Permixon® 160 mgPhase 41 trial
Permixon® 160 mgPhase 41 trial
Active Trials
NCT02121613Completed833Est. Jun 2016
NCT01604811Completed206Est. Oct 2013
HistoSonics
HistoSonicsMI - Ann Arbor
2 programs
Vortx Rx - Histotripsy BPH DeviceN/A1 trial
Vortx Rx - Histotripsy BPH DeviceN/A1 trial
Active Trials
NCT01896973Terminated28Est. Dec 2016
NCT01775488Withdrawn0
Olympus
OlympusPA - Center Valley
1 program
iTindN/A1 trial
Active Trials
NCT04757116Recruiting206Est. Dec 2031

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Pierre FabrePermixon® 160 mg
Pierre FabrePermixon® 160 mg
OlympusiTind
HistoSonicsVortx Rx - Histotripsy BPH Device
HistoSonicsVortx Rx - Histotripsy BPH Device

Clinical Trials (5)

Total enrollment: 1,273 patients across 5 trials

NCT02121613Pierre FabrePermixon® 160 mg

PERmixon® in LUTS Evaluation Study (PERLES)

Start: Apr 2014Est. completion: Jun 2016833 patients
Phase 4Completed
NCT01604811Pierre FabrePermixon® 160 mg

Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)

Start: Jun 2012Est. completion: Oct 2013206 patients
Phase 4Completed
NCT04757116OlympusiTind

Post-Market Study to Assess iTind Safety in Comparison to UroLift

Start: Sep 2022Est. completion: Dec 2031206 patients
N/ARecruiting
NCT01896973HistoSonicsVortx Rx - Histotripsy BPH Device

Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)

Start: Jul 2013Est. completion: Dec 201628 patients
N/ATerminated
NCT01775488HistoSonicsVortx Rx - Histotripsy BPH Device

Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)

Start: Jun 20130
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,273 patients
3 companies competing in this space